Ownership and insider activity for Lite Strategy, Inc. (LITS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Price
| Price | $1.02 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $8.5M | $15.7M | $16.9M | $3.7M | $18.0M |
| Short-term Investments | $144.9M | $137.5M | $83.8M | $34.6M | 0 |
| Receivables | $7.6M | $10.0M | $85000 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $164.8M | $167.1M | $107.5M | $40.8M | $18.3M |
| Property, Plant & Equipment | $9.3M | $10.7M | $13.3M | $606000 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $174.1M | $177.8M | $120.8M | $41.4M | $18.3M |
| Accounts Payable | $6.4M | $7.9M | $6.1M | $3.2M | $176000 |
| Short-term Debt | $928000 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $20.2M | $24.4M | $20.3M | $8.4M | $1.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $124.6M | $125.4M | $96.2M | $8.4M | $1.4M |
| Retained Earnings | -$319.7M | -$374.2M | -$406.0M | -$388.2M | -$404.2M |
| Total Equity | $49.5M | $52.4M | $24.6M | $33.0M | $16.9M |
| Total Debt | $8.3M | $9.6M | $12.7M | 0 | 0 |
| Net Debt | -$145.1M | -$143.6M | -$88.0M | -$38.3M | -$18.0M |
| Working Capital | $144.6M | $142.7M | $87.2M | $32.4M | $16.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.53 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -19.61 |
Profitability
| Return on Equity | -90.81% |
| Return on Invested Capital | -22.40% |
| Return on Assets | -105.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACET · ACRV · HOWL · IMUX · IOBT · NTRB · PMVP
Explore sector: Healthcare · Biotechnology
More sections of LITS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks